On February 6, 2023 BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, reported that Keir Loiacono, Chief Executive Officer of BlueSphere Bio, will present a corporate overview at the 2023 BIO CEO & Investor Conference held in New York City, NY from February 6-9, 2023 (Press release, BlueSphere Bio, FEB 6, 2023, View Source [SID1234626862]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The in-person presentation will highlight the Company’s first and lead product candidate, BSB-1001, currently being developed for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in conjunction with allogeneic hematopoietic stem cell transplantation (alloSCT). The Company anticipates filing its first investigational new drug application later this year.

Presentation details:
Date: Tuesday, February 7, 2023
Time: 10:30 a.m. ET
Location: Marriott Marquis Times Square

For more information about the BIO CEO & Investor Conference, please refer to the conference website at www.bio.org/events/bio-ceo-investor-conference.

On February 6, 2023 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the compensation committee of BioCryst’s board of directors granted 20 newly-hired employees stock options to purchase an aggregate of 287,200 shares, and restricted stock units (RSUs) covering an aggregate of 101,700 shares, of BioCryst common stock (Press release, BioCryst Pharmaceuticals, FEB 6, 2023, View Source [SID1234626861]). The options and RSUs were granted as of January 31, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The options have an exercise price of $10.55 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

On February 6, 2023 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, reported that the Company’s Compensation Committee granted 7 new employees inducement stock options to purchase an aggregate of 70,070 common shares, at a per share exercise price of $9.05, the closing price of Aurinia’s common stock on February 3, 2023, and an aggregate of 43,160 inducement restricted stock units (RSUs) (Press release, Aurinia Pharmaceuticals, FEB 6, 2023, View Source [SID1234626860]). The inducement stock options and RSUs have a grant date of February 6, 2023. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The inducement stock options have a ten-year term and vest over three years with one-third of the shares vesting on the twelve month anniversary from the grant date, and the remaining options vesting in twenty-four equal monthly installments thereafter.

The inducement RSUs shall vest in three equal annual installments on the first, second and third anniversary of the grant date.

On February 6, 2023 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported that the Company will release fourth quarter and full year 2022 financial results after market close on Wednesday, February 8, 2023 (Press release, Atara Biotherapeutics, FEB 6, 2023, View Source [SID1234626859]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 6, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act (Press release, Astellas, FEB 6, 2023, View Source [SID1234626858]). The Company also announced that it decided to cancel its treasury stock pursuant to the provisions of Article 178 of the Companies Act. The details are as follows.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.

Details of the acquisition of own shares
(1) Class of shares to be acquired:　　Common stock of the Company
(2) Total number of shares to be acquired:　　Up to 29 million shares
　　　　　　(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.59%)
(3) Total amount of acquisition cost:　　Up to 50 billion yen
(4) Period of acquisition:　　From February 7, 2023 to March 24 ,2023
(5) Method of acquisition:　　Marked purchase on the Tokyo Stock Exchange

Details of the cancellation of treasury stock
(1) Class of shares to be cancelled:　　Common stock of the Company
(2) Number of shares to be cancelled:　　All of the shares acquired as stated in 2 above
(3) Cancellation date:　　March 29, 2023 (planned)
＊ The actual number of shares to be cancelled will be announced after
completing the acquisition of own shares stated in 2 above.
(Reference) Status of treasury stock as of December 31, 2022:

Total number of shares outstanding (excluding treasury stock): 1,822,806,495 shares
Total number of treasury stocks: 13,045,080 shares